HEALTHglobal
Lilly’s three-pronged obesity drug hits goal in large diabetes trial
Single source
Updated 2 hours ago
First seen March 20, 2026 07:14:09Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Retatrutide, a possible advance on GLP-1 drugs like Zepbound, significantly cut blood sugar and body weight in the study, a sign it might be similarly impactful against obesity.